

CITATION REPORT

List of articles citing

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

DOI: 10.1007/s40273-017-0492-6
Pharmacoeconomics, 2017, 35, 537-547.

Source: <https://exaly.com/paper-pdf/66658661/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	Evidence for more intensive cholesterol lowering. <i>Current Opinion in Lipidology</i> , 2017 , 28, 291-299	4.4	11
15	The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. <i>Current Opinion in Lipidology</i> , 2017 , 28, 470-476	4.4	1
14	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. <i>International Journal of Clinical Practice</i> , 2017 , 71, e13032	2.9	25
13	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , 2018 , 41, 544-550	3.3	6
12	Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 1027-1035	1.5	18
11	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 9-15	5.5	10
10	Are PCSK9 Inhibitors Cost Effective?. <i>Pharmacoeconomics</i> , 2018 , 36, 1031-1041	4.4	14
9	Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 1027-1035	0.7	5
8	Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 461-474	2.2	2
7	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005404	5.8	29
6	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 286, 40-45	3.1	6
5	Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia. <i>Current Opinion in Lipidology</i> , 2019 , 30, 263-272	4.4	6
4	Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. <i>Atherosclerosis</i> , 2019 , 281, 207-212	3.1	23
3	What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 104457	2.8	2
2	Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register. <i>Current Opinion in Lipidology</i> , 2020 , 31, 167-175	4.4	2
1	Evaluaci3n econ3mica de evolocumab en pacientes con enfermedad cardiovascular de alto riesgo con hipercolesterolemia primaria y dislipidemia mixta no controlados. 2022 , 33, 52-63		0